Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 0: clinchem.2008.103721v1, 2008; 10.1373/clinchem.2008.103721
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
clinchem.2008.103721v1
54/7/1141    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wong, L.-J. C.
Right arrow Articles by Chinault, A. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wong, L.-J. C.
Right arrow Articles by Chinault, A. C.

Received on January 22, 2008
Accepted on April 2, 2008

Molecular Diagnostics and Genetics

Utility of Oligonucleotide Array–Based Comparative Genomic Hybridization for Detection of Target Gene Deletions

Lee-Jun C. Wong 1*, David Dimmock 1, Michael T. Geraghty 2, Richard Quan 3, Uta Lichter-Konecki 4, Jing Wang 1, Ellen K. Brundage 1, Fernando Scaglia 1, A. Craig Chinault 1

1 Molecular and Human Genetics, Baylor College of Medicine, Houston, TX
2 Genetics, Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada
3 UC Davis Medical Center, Sacramento, CA
4 Children's National Medical Center, Washington, DC

* To whom correspondence should be addressed. E-mail: ljwong{at}bcm.edu.

BACKGROUND: Direct DNA sequencing is the primary clinical technique for identifying mutations in human disease, but sequencing often does not detect intragenic or whole-gene deletions. Oligonucleotide array–based comparative genomic hybridization (CGH) is currently in clinical use to detect major changes in chromosomal copy number.

METHODS: A custom oligonucleotide-based microarray was constructed to provide high-density coverage of an initial set of 130 nuclear genes involved in the pathogenesis of metabolic and mitochondrial disorders. Standard array CGH procedures were used to test patient DNA samples for regions of copy number change. Sequencing of regions of predicted breakpoints in genomic DNA and PCR analysis were used to confirm oligonucleotide array CGH data.

RESULTS: Oligonucleotide array CGH identified intragenic exonic deletions in 2 cases: a heterozygous single-exon deletion of 4.5 kb in the SLC25A13 gene [solute carrier family 25, member 13 (citrin)] in an individual with citrin deficiency and a homozygous 10.5-kb deletion of exons 13–17 in the ABCB11 gene [PFIC2, ATP-binding cassette, sub-family B (MDR/TAP), member 11] in a patient with progressive familial intrahepatic cholestasis. In 2 females with OTC deficiency, we also found 2 large heterozygous deletions of approximately 7.4 Mb and 9 Mb on the short arm of the X chromosome extending from sequences telomeric to the DMD gene [dystrophin (muscular dystrophy, Duchenne and Becker types)] to sequences within or centromeric to the OTC gene (ornithine carbamoyltransferase).

CONCLUSIONS: These examples illustrate the successful use of custom oligonucleotide arrays to detect either whole-gene deletions or intragenic exonic deletions. This technology may be particularly useful as a complementary diagnostic test in the context of a recessive disease when only one mutant allele is found by sequencing.




The following articles in journals at HighWire Press have cited this article:


Home page
Clin. Chem.Home page
Y. Shen and B.-L. Wu
Microarray-Based Genomic DNA Profiling Technologies in Clinical Molecular Diagnostics
Clin. Chem., April 1, 2009; 55(4): 659 - 669.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2008 by the American Association for Clinical Chemistry.